Resistia Corporation

Resistia Corporation is an Argentina-based biotechnology research company founded in 2025. The company has developed a platform that leverages over 15 years of research into commensal microbiota to isolate specialized molecules capable of disrupting biofilms. These microbiota-derived compounds are designed to outcompete pathogens and re-empower existing antibiotics without triggering further resistance. The technology is focused on addressing the global challenge of antimicrobial resistance (AMR), specifically targeting biofilm-related infections, which are responsible for a significant portion of chronic human infections and can render bacteria 1,000 times more resistant to conventional antibiotic treatments.

This technology is intended to bridge the global AMR gap by providing therapeutic solutions for conditions such as chronic wounds and cystic fibrosis. By restoring the efficacy of life-saving antibiotics, Resistia aims to address a massive, underserved medical market where current enzyme-based alternatives often lack sufficient stability or effectiveness. Backed by investors including GRIDX and INCATE, and selected for the Spring 2026 Blueprint Cohort at The Engine, the company is actively working to commercialize its platform to combat the silent pandemic of antibiotic-resistant biofilm infections.